In pediatric AML, the most relevant immune-based therapy approach consists of targeting surface antigens, particularly CD33 (sialic-acid-binding immunoglobulin lectin, SIGLEC) and CD123 (IL3Rα), both highly expressed, although not exclusively, by AML cells [58]. This evidence concerns the gene CD33 and acute myeloid leukemia.